Precision Tumor Recognition by T Cells with Combinatorial Antigen-Sensing Circuits

Cell

Volumn 164, Issue 4, 2016, Pages 770-779

  Roybal, Kole T ^a,b,c   Rupp, Levi J ^a,b,c   Morsut, Leonardo ^a,b,c   Walker, Whitney J ^a,b,c   McNally, Krista A ^a,b,c   Park, Jason S ^a,b,c   Lim, Wendell A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL RECEPTOR; CHIMERIC ANTIGEN RECEPTOR; NOTCH RECEPTOR; SYNTHETIC NOTCH RECEPTOR; UNCLASSIFIED DRUG; CD19 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE ANTIGEN; MESOTHELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; BYSTANDER EFFECT; CELL COMMUNICATION; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; JURKAT CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD19; ANTIGENS, SURFACE; BYSTANDER EFFECT; CELL COMMUNICATION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; RECEPTORS, NOTCH; T-LYMPHOCYTES;

EID: 84958214384     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.01.011     Document Type: Article

References (20)

1. D.M. Barrett, N. Singh, D.L. Porter, S.A. Grupp, and C.H. June Chimeric antigen receptor therapy for cancer Annu. Rev. Med. 65 2014 333 347
2. D.M. Barrett, D.T. Teachey, and S.A. Grupp Toxicity management for patients receiving novel T-cell engaging therapies Curr. Opin. Pediatr. 26 2014 43 49
3. R.J. Brentjens, M.L. Davila, I. Rivière, J. Park, X. Wang, L.G. Cowell, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, and et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci. Transl. Med. 5 2013 177ra38
4. G. Dotti, S. Gottschalk, B. Savoldo, and M.K. Brenner Design and development of therapies using chimeric antigen receptor-expressing T cells Immunol. Rev. 257 2014 107 126
5. V.D. Fedorov, M. Themeli, and M. Sadelain PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses Sci. Transl. Med. 5 2013 215ra172
6. P.C. Fridy, Y. Li, S. Keegan, M.K. Thompson, I. Nudelman, J.F. Scheid, M. Oeffinger, M.C. Nussenzweig, D. Fenyö, B.T. Chait, and M.P. Rout A robust pipeline for rapid production of versatile nanobody repertoires Nat. Methods 11 2014 1253 1260
7. W.R. Gordon, B. Zimmerman, L. He, L.J. Miles, J. Huang, K. Tiyanont, D.G. McArthur, J.C. Aster, N. Perrimon, J.J. Loparo, and S.C. Blacklow Mechanical Allostery: Evidence for a Force Requirement in the Proteolytic Activation of Notch Dev. Cell 33 2015 729 736
8. S.A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D.L. Porter, S.R. Rheingold, D.T. Teachey, A. Chew, B. Hauck, J.F. Wright, and et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med. 368 2013 1509 1518
9. C.H. June, B.R. Blazar, and J.L. Riley Engineering lymphocyte subsets: tools, trials and tribulations Nat. Rev. Immunol. 9 2009 704 716
10. C.C. Kloss, M. Condomines, M. Cartellieri, M. Bachmann, and M. Sadelain Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells Nat. Biotechnol. 31 2013 71 75
11. C.H.J. Lamers, S. Sleijfer, A.G. Vulto, W.H.J. Kruit, M. Kliffen, R. Debets, J.W. Gratama, G. Stoter, and E. Oosterwijk Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience J. Clin. Oncol. 24 2006 e20 e22
12. F. Lienert, J.J. Lohmueller, A. Garg, and P.A. Silver Synthetic biology in mammalian cells: next generation research tools and therapeutics Nat. Rev. Mol. Cell Biol. 15 2014 95 107
13. W.A. Lim Designing customized cell signalling circuits Nat. Rev. Mol. Cell Biol. 11 2010 393 403
14. R.A. Morgan, J.C. Yang, M. Kitano, M.E. Dudley, C.M. Laurencot, and S.A. Rosenberg Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol. Ther. 18 2010 843 851
15. R.A. Morgan, N. Chinnasamy, D. Abate-Daga, A. Gros, P.F. Robbins, Z. Zheng, M.E. Dudley, S.A. Feldman, J.C. Yang, R.M. Sherry, and et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy J. Immunother. 36 2013 133 151
16. L. Morsut, K.T. Roybal, X. Xiong, R.M. Gordley, S.M. Coyle, M. Thomson, and W.A. Lim Engineering customized cell sensing and response behaviors using synthetic notch receptors Cell 164 2016 780 791 this issue
17. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N. Engl. J. Med. 365 2011 725 733
18. B.A. Rabinovich, Y. Ye, T. Etto, J.Q. Chen, H.I. Levitsky, W.W. Overwijk, L.J.N. Cooper, J. Gelovani, and P. Hwu Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer Proc. Natl. Acad. Sci. USA 105 2008 14342 14346
19. M. Sadelain, R. Brentjens, and I. Rivière The promise and potential pitfalls of chimeric antigen receptors Curr. Opin. Immunol. 21 2009 215 223
20. S. Wilkie, M.C.I. van Schalkwyk, S. Hobbs, D.M. Davies, S.J.C. van der Stegen, A.C.P. Pereira, S.E. Burbridge, C. Box, S.A. Eccles, and J. Maher Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling J. Clin. Immunol. 32 2012 1059 1070